Medical News Observer

Key Points

• MOZI Treatment Planning System (MOZI TPS) integrates multiple core functionalities, including image processing, structure delineation, treatment plan design, optimization, and evaluation, making it a comprehensive tool for radiotherapy planning.
• Manteia Technologies Co., Ltd., based in Xiamen, China, developed MOZI TPS. The U.S. FDA has approved it as a Class II medical device, ensuring compliance with stringent safety and effectiveness standards.
• This system is specifically indicated for external beam irradiation using photon beams and is designed to meet a wide range of radiotherapy planning needs.

 

Device Information

The MOZI Treatment Planning System (MOZI TPS) is a standalone software system that plans radiotherapy treatments for patients with malignant and benign diseases. Its core functionalities include image processing, structure delineation, plan design, optimization, and evaluation. It employs Monte Carlo methods for dose calculation and deep learning for automatic contouring of structure delineation.

Manufacturer Information

MOZI TPS was developed by Manteia Technologies Co., Ltd., based in Xiamen, China. The company specializes in creating sophisticated treatment planning systems for radiation therapy, contributing to advancements in the precision and effectiveness of cancer treatments.

Regulatory Approval Information

MOZI TPS is classified as a Class II medical device under regulation 21 CFR 892.5050, per U.S. FDA standards. This software device meets the Medical Charged-Particle Radiation Therapy System requirements. It is substantially equivalent to predicate devices under the 510(k) premarket notification.

Indications

MOZI TPS software is used to plan external beam irradiation with photon beams. It caters to a broad spectrum of radiotherapy planning needs, including those for malignant and benign conditions.

Contraindications

As a software-based device, MOZI TPS does not directly contact patients and thus does not have conventional medical device contraindications. It requires operation by trained medical professionals in appropriate clinical settings.

Study Results

The MOZI TPS has undergone extensive testing to verify its performance and safety. The system’s algorithm for dose calculation, deformable registration, and structure delineation has been validated against recognized standards and predicate devices, demonstrating non-inferiority in performance outcomes.

Limitations

While MOZI TPS offers significant advantages in radiotherapy planning, it depends on accurate input data and requires skilled operation by medical professionals. Limitations include its reliance on system compatibility with specific imaging devices and the inherent challenges of adapting AI and machine learning algorithms to complex clinical scenarios.

Conclusion

The MOZI TPS is a robust and reliable software tool that enhances the capabilities of healthcare providers in planning effective radiation therapy treatments. It meets high regulatory standards and has proven to be an effective tool in modern medical devices for cancer treatment.

Future Implications

The ongoing development of MOZI TPS could possibly include improvements in AI capabilities, greater integration with various imaging systems, and further automation of treatment planning processes. These advancements could lead to more customized treatment plans and better outcomes for radiation therapy patients. 

Reference

“MOZI TPS K 223724 510(k) Premarket Notification.” Accessed online. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K223724.